CLX insider: 9,293 shares acquired at $122.25 on 10/03/2025
Insider transaction summary: An executive officer of Clorox Co. (CLX) reported transactions on 10/03/2025 that settled a 2022 performance-unit grant into 9,293 shares of common stock at a per-share price of $122.25.
Rhea-AI Filing Summary
Insider transaction summary: An executive officer of Clorox Co. (CLX) reported transactions on 10/03/2025 that settled a 2022 performance-unit grant into 9,293 shares of common stock at a per-share price of $122.25. The filing shows two share withholdings to satisfy tax obligations: 1,653 shares and 3,488 shares, each recorded at $122.25. Following these transactions the reporting person beneficially owns 38,280 shares (this total includes 534 shares from dividend reinvestment). The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Positive
- 9,293 shares acquired from settlement of a 2022 performance unit grant on 10/03/2025
- 534 shares added via the dividend reinvestment feature of the Stock Incentive Plan
Negative
- 1,653 shares withheld to satisfy tax obligations related to restricted stock vesting
- 3,488 shares withheld to satisfy tax obligations related to performance stock units
Insights
Settlement and tax withholdings show routine executive equity compensation activity.
The settlement of a 2022 performance unit grant into 9,293 shares on 10/03/2025 is a standard compensation event converting long‑term incentives into stock, which increases immediate share count for the reporting person.
Withholding of 1,653 and 3,488 shares to satisfy taxes reduced the net shares delivered; this is a common liquidity-freeway to meet withholding obligations. Watch for annual equity grant schedules near year‑end for similar entries.
Reported holdings of 38,280 shares reflect post‑transaction beneficial ownership and include dividend reinvestment.
The filing discloses direct ownership only and notes 534 shares came from a dividend reinvestment feature, indicating participation in the company's stock plan. The transaction codes and explanations show no sales for liquidity beyond tax withholding.
For governance monitoring, confirm periodic director/officer holdings versus company equity‑ownership guidelines and note that the Form was executed by an attorney‑in‑fact on 10/07/2025.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 9,293 | $122.25 | $1.14M |
| Exercise Price or Tax Liability | Common Stock | 1,653 | $122.25 | $202K |
| Exercise Price or Tax Liability | Common Stock | 3,488 | $122.25 | $426K |
Footnotes (4)
- F1. Settlement of 2022 Performance Unit Grant that vested 10/3/25.
- F2. Withholding of shares by the Company to satisfy tax obligations relating to vesting of restricted stock.
- F3. Withholding of shares by the Company to satisfy tax obligations relating to vesting of performance stock units.
- F4. Includes 534 shares acquired pursuant to a dividend reinvestment feature of the Company's Stock Incentive Plan.
FAQ
What did the CLX Form 4 filed by the executive report on 10/03/2025?
What price was used for the transactions in the CLX Form 4?
Does the Form 4 indicate any open‑market sales by the reporting person?
Who signed the CLX Form 4 and when was it signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.